Krebs Biochemicals & Industries Limited (KREBSBIO.NS)

INR 99.85

(1.11%)

Market Cap (In INR)

2.15 Billion

Revenue (In INR)

504.21 Million

Net Income (In INR)

-197.28 Million

Avg. Volume

124.19 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
60.35-129.07
PE
-
EPS
-
Beta Value
0.455
ISIN
INE268B01013
CUSIP
Y4987T116
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Jitendra Rameshchandra Shah
Employee Count
-
Website
https://krebsbiochem.com
Ipo Date
2016-10-27
Details
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.